The Obesity Treatment Pipeline is an evolving system targeting the global obesity crisis with innovative drug and non-drug therapies focused on long-term health benefits, sustainability, and personalized care. Key developments include incretin-based therapies like GLP-1 and GIP agonists (e.g., semaglutide, tirzepatide), CNS-acting drugs that regulate hunger, amylin and leptin modulators for hormonal regulation, and oral small-molecule drugs offering better patient compliance. Non-pharmacological interventions such as gastric balloons and nerve stimulation expand options beyond conventional treatments. These multi-pronged approaches aim to manage obesity and comorbidities like diabetes and hypertension, reduce healthcare costs, and support scalable, accessible solutions for a healthier global population.
